QUOTE AND NEWS
Forbes  2 hrs ago  Comment 
Analysts expect higher profit for Sanofi when the company reports its second quarter results on Thursday, July 31, 2014. The consensus estimate is calling for profit of 79 cents a share, reflecting a rise from 73 cents per share a year ago.The...
FierceBiotech  4 hrs ago  Comment 
Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew of Phase III trials in which the drug slashed patients' bad cholesterol.
StreetInsider.com  6 hrs ago  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Regeneron+%28REGN%29%2C+Sanofi+%28SNY%29+Announce+Positive+Top-Line+Phase+3+ODYSSEY+Data/9701895.html for the full story.
SeekingAlpha  Jul 28  Comment 
By M Plaut: When Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) announced at the end of May that the FDA had denied it Breakthrough Therapy Designation (BTD) it caused a sharp drop in the stock price. The extreme move in the stock market...
StreetInsider.com  Jul 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/InnerWorkings+%28INWK%29+Becomes+Global+Marketing+Partner+for+Sanofi+%28SNY%29/9693589.html for the full story.
newratings.com  Jul 25  Comment 
CANONSBURG (dpa-AFX) - French drugmaker Sanofi ( SNYNF, SNY) is said to have taken interest from private-equity firms such as KKR & Co.(KKR), Blackstone Group (BX) and TPG Capital, for the sale of its portfolio of older, off-patent drugs,...
The Economic Times  Jul 23  Comment 
Net sales of the company went up by 18.70 per cent to Rs 486.7 crore during the quarter under review as against Rs 410 crore during the same period a year ago.
Motley Fool  Jul 22  Comment 
Sanofi (SNY) and Novartis (NVS) generic units are among those challenging the dosing patent on Biogen's (BIIB) Tecfidera.




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki